Lilly(US:LLY) Zheng Quan Shi Bao Wang·2025-12-02 00:17Core Viewpoint - Eli Lilly announced a price reduction for Zepbound, making it more affordable for self-paying patients through the LillyDirect platform, in response to market pressures and competition [1] Pricing Strategy - Starting December 1, the self-pay price for Zepbound will decrease from a range of $349-$499 per month to $299-$449 per month [1] - The initial dosage will be priced at $299 per month, the 5 mg dosage at $399, and all higher dosages will be uniformly priced at $449 [1] - The original list price for Zepbound was approximately $1,086 per month [1] Market Context - This price reduction targets self-injecting patients using single-dose vials of Zepbound, aiming to alleviate barriers caused by high list prices and unstable insurance coverage [1] - The price cut follows an agreement during the Trump administration aimed at lowering prices for GLP-1 medications, with competitors like Novo Nordisk also recently reducing prices for their weight loss drug Wegovy and diabetes medication Ozempic [1]